LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Biologics/Tennis Star Treated With Stem Cells
Biologics

Tennis Star Treated With Stem Cells

November 26, 2014 1 min read Premium comments

Advertisement

Tennis Star Treated With Stem Cells
Rafael Nadal / Source: Wikimedia Commons and Tabercil
Secondary

The doctor for international tennis star Rafael Nadal has told The Associated Press that he plans to inject stem cells in the players ailing back next week in Barcelona. Nadal is the 14-time Grand Slam winner who won a record ninth French Open this season.

Nadal’s doctor, Angel Ruiz-Cotorro, said that the player’s back pain is “typical of tennis players.” The doctor said that the stem cell treatment is designed to repair cartilage and is similar to the stem cell treatment Nadal received on his knee last year. Ruiz-Cotorro reported that the cells to be used are Nadal’s own, extracted earlier this year, and cultivated “to “produce the necessary quantity” of cells.

“When we have them we will put them in the point of pain, ” the doctor said, with the goal of “regenerating cartilage, in the midterm, and producing an anti-inflammatory effect.”

According to the press release, several NFL players and baseball players have received stem cell treatment. Nadal’s fellow Spaniard Pau Gasol, center of the Chicago Bulls, received stem cell treatment on his knee in 2013. Nadal’s record of winning 14 Grand Slam titles ties him with Pete Sampras on the all-time list led by Roger Federer who had 17 victories.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy